Cell Line Development Market Trends

Growth Drivers

• Rising Burden of Osteoporosis

According to the International Osteoporosis Foundation, every year, osteoporosis causes more than 8.9 million fractures worldwide, culminating in an osteoporosis fracture every 3 seconds.

To deal with growing osteoporosis monoclonal antibodies are prepared which is known are stimulating antibodies in patient. Hence owing to this the market is expected to boost in the forecast period.

• Growing Risk of Coronavirus

As of February 2022, there had been approximate 5 million confirmed deaths due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide, which has caused over 400 million cases.

• Increasing Risk of Cancer Causing Disease

According to the World Health Organization, about 30% of cancer cases in low- and lower-middle-income nations are caused by cancer-causing diseases such the human papillomavirus (HPV) and hepatitis.

• Growing Nervous Systems Disorder Cases

According to the European Academy of Neurology, over the past 30 years, the incidence of deaths from neurological disorders has climbed by approximately 40%, with 1 in 3 persons experiencing a neurological ailment at some point in their lives.

• Cell Line Development Based On Mammalian Cell Culture

Mammalian cell culture has recently become essential to the biomanufacturing of viral vaccines and therapeutic proteins. Through viral infection, these cells create vaccines, and through genetic engineering, they produce therapeutic proteins.

Challenges

• Inability to Produce or Develop a Stable and Authentic Cell
• Low Transfection Efficiency
• Integration Frequency

Stable cell lines are a crucial laboratory tool for screening experimental medications, researching gene function, and generating therapeutic proteins because they express significant amounts of the protein of interest. However, a variety of elements, including the use of a DNA vector, reagents, the choice of cell lines, and the transfection technique, are equally crucial in creating a stable cell line. Additionally, the stability of cell lines will suffer from any modifications or adjustments to these variables. Hence this factor could hinder the growth of the market.

The global cell line development market is segmented and analysed for demand and supply by cell type into CHO cells, BHK 21 cells, NSO cells, murine C127 cells, NIH3T3 cells, L929 cells, and others. Out of which, BHK 21 cells segment is anticipated to garner the revenue of USD 2,455.4 Million by the end of 2031, by growing at a highest CAGR of 12.84% during the forecast period. In 2021 the revenue of BHK 21 cells segment stood at USD 737.8 Million.  Increasing cases of rabies is expected to boost the market growth. BHK 21 cells are most frequently used cells lines. They are extensively used for treating rabies. The World Organization for Animal Health use these BHK21 cells in the regular diagnosis of rabies. To thrive in serum- or animal-component-free cell medium for the manufacture of rabies vaccines, BHK21 cells appear to have already undergone the necessary adaptations. Additionally CHO cells segment is anticipated to garner the largest revenue of USD 5,396.4 Million by the end of 2031.